

Report Title	Monthly Risk Register Report		
Sponsoring Executive	Kam Dhami, Director of Governance		
Report Author	Sindeep Chatha, Head of Patient Safety and Risk		
Meeting	Trust Board (Public)	Date	4 th March 2021

1. Suggested discussion points *[two or three issues you consider the Trust Board should focus on]*

There are 12 risks overseen by the Board with upcoming action deadlines, updates on each risk are provided in this report.

The following actions were agreed at the February's RMC and CLE:

- Two risks have been mitigated and are being proposed for removal.
- Four risks need extensions for the mitigating actions to have a positive effect in reducing the risk

Board to Note:

- One new risk has been put forward for Board oversight (FFP3 masks on amber wards)
- Early in the Pandemic concerns were raised as to whether there was adequate oxygen supply, given the increase in requirements. The risk has not materialised as the usage has not risen above 60%.

2. Alignment to 2020 Vision *[indicate with an 'X' which Plan this paper supports]*

Safety Plan	<input type="checkbox"/>	Public Health Plan	<input type="checkbox"/>	People Plan & Education Plan	<input type="checkbox"/>
Quality Plan	<input type="checkbox"/>	Research and Development	<input type="checkbox"/>	Estates Plan	<input type="checkbox"/>
Financial Plan	<input type="checkbox"/>	Digital Plan	<input type="checkbox"/>	Other <i>[specify in the paper]</i>	<input checked="" type="checkbox"/>

3. Previous consideration *[where has this paper been previously discussed?]*

Risk Management Committee, 15th February 2021, CLE, 24th February 2021

4. Recommendation(s)

The Trust Board is asked to:

- APPROVE** removal of two risks (3021 and 3212) from Board Oversight
- NOTE** the extension requests for four risks
- APPROVE** risk relating to FFP3 masks on amber wards

5. Impact *[indicate with an 'X' which governance initiatives this matter relates to and where shown elaborate]*

Trust Risk Register	<input checked="" type="checkbox"/>	Risk Number(s):				
Board Assurance Framework	<input checked="" type="checkbox"/>	Risk Number(s):				
Equality Impact Assessment	Is this required?	Y	<input type="checkbox"/>	N	<input checked="" type="checkbox"/>	If 'Y' date completed
Quality Impact Assessment	Is this required?	Y	<input type="checkbox"/>	N	<input checked="" type="checkbox"/>	If 'Y' date completed

SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST

Report to the Trust Board: 4th March 2021

Monthly Risk Register Report

1.0 INTRODUCTION

1.1 This report provides the Trust Board with an update on the risks it has oversight on, held within the Trust's risk register. The report outlines progress in improving the robustness of the Trust's risk management arrangements with a review of the Risk Register entries.

1.2 The Trust has identified a range of significant risks that are currently being mitigated, whose impact could have a direct bearing on the achievement of Trust Plans and priorities and requirements within the NHSI Accountability Framework or CQC registration, should the mitigation plans be ineffective.

1.3 A summary of the main controls and mitigating actions for the significant risks currently identified in each Clinical Group and Corporate Directorate monitored by the Trust Board are available in **Appendix A**.

2.0 TRUST BOARD RISK REGISTER REVIEW

2.1 Of the 12 risks overseen by the Board, two are being proposed for removal as the risks have been mitigated. Four risks continue to require extensions to their mitigation plans or awaiting further assurance data that plans have resolved the risk and these can be seen below.

Risk ID	Executive Risk Lead	Title	Current rating	Target rating	Change
534	Medical Director's Office	Lack of UHB Oncologist attendance at MDT	4x1 =4	2x1=2	↔
Update	All actions for this risk have been completed. The risk remains whilst awaiting more assurance that the Oncologists attend post COVID..				
Recommendation	RMC to keep this risk on Board oversight and review again in April				

Risk ID	Executive Risk Lead	Title	Current rating	Target rating	Change
2624	Medical Director's Office	Result Endorsement	3x5-15	1x5= 5	↔
Update	There are improved controls in place, with 70% of results being endorsed. Radiology reports receive a 'red flag' notification when an anomaly has been found and a routine report is now received in Groups for unsolicited results. For pathology results, significant abnormal results are now phoned through to the clinical team. Work continues to assure the approaches being taken helps risk mitigation				

Recommendation	CLE agreed to extend the deadline for this risk by end of August 2021
-----------------------	--

Risk ID	Executive Risk Lead	Title	Current rating	Target rating	Change
2624	Medical Director's Office	Result Endorsement	3x5=15	1x5= 5	↔
Update	There are improved controls in place, with 70% of results being endorsed. Radiology reports receive a 'red flag' notification when an anomaly has been found and a routine report is now received in Groups for unsolicited results. For pathology results, significant abnormal results are now phoned through to the clinical team. Work continues to assure the approaches being taken helps risk mitigation				

Recommendation	CLE agreed to extend the deadline for this risk to be mitigated by end of August 2021
-----------------------	--

Risk ID	Executive Risk Lead	Title	Current rating	Target rating	Change
3693	Medical Director's Office	Trust Amenable Mortality	4x4 =16	3x4=12	↔
Update	VTE prophylaxis and QI work for pneumonia, mouth care and UTI to reduce risk of mortality from sepsis continues. Other work taking place is reviewing the approach to coding as well as palliative care, but factors which have worsened the HSMR position is due to Covid deaths not being separated from non-Covid deaths and as a result so affecting the HSMR data. Work and pathway to this is presented at Quality and Safety to illustrate work being done and affect this will have on mortality if achieved.				

Recommendation	CLE agreed to review this risk again in April
-----------------------	--

Risk ID	Executive Risk Lead	Title	Current rating	Target rating	Change
3021	Chief Executive	MMUH procurement	2x4=8	2x4=8	↓
Update	All actions for this risk have been completed and a new contract has been signed with Balfour Beatty.				

Recommendation	CLE agreed to remove for Board oversight
-----------------------	---

Risk ID	Executive Risk Lead	Title	Current rating	Target rating	Change
3212	Chief Operating Officer	BMEC Standalone images on PAC	3x1=3	3x1=3	↓
Update	All actions for this risk have been completed. The PAC system and process has now been set up and tested. This is no longer a risk.				

Recommendation	CLE agreed to remove for Board oversight
-----------------------	---

3.0 RED RISKS

3.1 In addition to the risks above being discussed, attention focused on two other risks which were raised with RMC, one for information and one for approval.

- 3.2** Due to the COVID 19 pandemics effect on patients and the increased requirement for Oxygen supplies, Estates Major Project Authority were sighted on whether there was sufficient capability to provide the required oxygen.
- 3.3** In the months since the risk was raised, Estates have identified that there are local pressures in the system, such as D17, the Respiratory hub and Critical Care Services. CCS at SWB is backed up outside of the existing supply, which will continue through to MMUH.
- 3.4** SWB has, to date, not exceeded 60% of the system capabilities thus the risk of not having adequate supplies is reduced.
- 3.5** The other risk discussed is a positive risk, in that SWB has gone contrary to national guidance in its use of FFP3 masks on Amber wards. This situation will continue to be assessed based on the numbers and type of patient admissions, whilst identifying what the trigger points for de-escalating the use of FFP3 masks is on each Amber ward.
- 3.6** Staff have advised that they feel positive about this action and about it being monitored on an ongoing basis through infection control.

4.0 RECOMMENDATIONS

The Trust Board is asked to:

- a. **APPROVE** removal of two risks (3021 and 3212) from Board Oversight
- b. **NOTE** the extension requests for four risks
- c. **DISCUSS** the risk relating to FFP3 masks on amber wards

Sindeep Chatha
Head of Patient Safety & Risk

25th February 2020